 Nov 1 2022
Recent article published in Molecular Oncology with MedRod® implants i...
|
 |
| PRICE QUOTE AND TECHNICAL INQUIRIES |
FOLLOW US
 |
|
|
DihydrotestosteroneFor mice and rats in metabolic and prostate cancer xenograft, PDX and syngeneic studiesDihydrotestosterone (DHT) implants for preclinical in vivo studies.
Drug release: At least 100 days
Dose range: 10 µg – 100 µg/day.
|  | |
|
